(Q49075893)

English

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

scientific article published in June 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. (English)

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Van Cauwenberge P

1

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

Juniper EF

2

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

publication date

1 June 2000

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

Clinical & Experimental Allergy

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

30

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

6

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

891-899

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Interpretation of rhinoconjunctivitis quality of life questionnaire data

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Interpreting treatment effects in randomised trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

The nasal mast cell and rhinitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

The systemic safety of fexofenadine HCl.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Second-generation antihistamines: the risk of ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Cardiovascular safety of fexofenadine HCl.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Measuring health-related quality of life in rhinitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Health-related quality of life in moderate asthma: 400 microg hydrofluoroalkane beclomethasone dipropionate vs 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2222.2000.00914.X

21 January 2018

Identifiers

10.1046/J.1365-2222.2000.00914.X

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/10848909

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49075893&oldid=1561790494"